Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDH1 R132H peptide vaccine |
| Synonyms | |
| Therapy Description |
IDH1 R132H peptide vaccine is a cancer vaccine comprising a peptide that includes the IDH1 R132H mutation, which may increase immune response against tumor cells harboring IDH1 R132H, resulting in decreased tumor growth (PMID: 25043048). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDH1 R132H peptide vaccine | IDH1 R132H peptide vaccine is a cancer vaccine comprising a peptide that includes the IDH1 R132H mutation, which may increase immune response against tumor cells harboring IDH1 R132H, resulting in decreased tumor growth (PMID: 25043048). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132H | malignant astrocytoma | predicted - sensitive | IDH1 R132H peptide vaccine | Phase I | Actionable | In a Phase I trial (NOA-16), treatment with IDH1 R132H peptide vaccine demonstrated safety in patients with malignant astrocytoma harboring IDH1 R132H and led to stable disease in 87.5% (28/32) of patients (J Clin Oncol 36, no. 15_suppl (May 20, 2018) 2001; NCT02454634). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03893903 | Phase I | Avelumab IDH1 R132H peptide vaccine Avelumab + IDH1 R132H peptide vaccine | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC) | Completed | DEU | 0 |